Skip to content
Clinical Trials – home
Therapeutic area

Immune system disorders – page 42

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Study on Upadacitinib and Tocilizumab for Children and Teens with Active Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Tocilizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Reducing Rituximab Dosage for Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:UZ Leuven

Study on Zilucoplan Sodium for Children Aged 2 to 17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:ZILUCOPLAN
  • Sponsor:UCB Biopharma

Asthma

Recruiting

Study on Tezepelumab for Children Aged 5 to 11 with Severe Asthma

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Study on the Effects of Dobutamine on Heart Function in Patients with Wild-type Transthyretin Amyloid Cardiomyopathy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Dobutamine
  • Sponsor:Region Midtjylland

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Study on Ciclosporin for Treating Atopic Keratoconjunctivitis in Adults

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Region Hovedstaden

Study on the Long-Term Safety of Zilucoplan in Children with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:ZILUCOPLAN
  • Sponsor:UCB Biopharma

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Dermatomyositis+2

Recruiting

Study on Filgotinib for Patients with Refractory Behcet's Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Filgotinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.